青蒿琥酯与奎宁MAX治疗恶性疟疾的最小成本分析  

Artesunate versus Quinine MAX for Malaria:Cost-minimization Analysis

作　　者：孙卫华[1] 

机构地区：[1]浙江省嘉兴市第一医院,嘉兴市314000

出　　处：《中国药房》2008年第32期2486-2488,共3页China Pharmacy

摘　　要：目的:评价青蒿琥酯(ART)与奎宁MAX(QUI)治疗恶性疟疾的经济学效果。方法:将64例恶性疟疾患者随机分为ART组与QUI组,分别应用ART和QUI依法治疗7d,考察2种用药方案的疗效并进行最小成本分析。结果:ART组、QUI组总有效率分别为90.6%、87.5%(P>0.05),平均成本分别为341、485元,差异有统计学意义(P<0.01)。结论:ART组治疗方案较佳,适宜于非洲等恶性疟疾高发区域推广使用。OBJECTIVE： To evaluate the economic effects of artesunate （ART） versus Quinine MAX （QUI） in treating malaria. METHODS： A total of 64 patients with malaria were randomly assigned to receive ART or QUI for 7 days, with cost- minimization analysis conducted on the 2 therapeutic scheme. RESULTS： The average cost for ART vs. QUI scheme was 341 yuan vs. 485 yuan, showing significant differences between the 2 schemes （P〈0.01） . The total effective rate was 90.6% for ART vs. 87.5% for QUI （P〉0.05）. CONCLUSION： The artesunate is preferable compared with QUI and could be popularized in poverty- striken area such as Africa.

关 键 词：青蒿琥酯 奎宁MAX 疟疾 最小成本分析 

分 类 号：R956[医药卫生—药学] R978.61